U.S. Auto Stock News

In March 2026, RapidFort announced a partnership to integrate its automated software supply chain security with the Nutanix Kubernetes Platform, while Nutanix also introduced its Nutanix Agentic AI solution built with NVIDIA to help enterprises run Agentic AI workloads securely at scale. Together, these moves deepen Nutanix’s role at the intersection of AI infrastructure, Kubernetes, and software supply chain security, potentially increasing the stickiness and breadth of its hybrid...

MARA’s Bitcoin sale and debt buyback: why it matters MARA Holdings (MARA) sold 15,133 Bitcoin for about US$1.1b to repurchase US$1b of 0% convertible notes due 2030 and 2031 at a 9% discount, reshaping its balance sheet. This move reduces debt, cuts potential future dilution and signals a tilt away from pure Bitcoin mining toward digital energy and AI or high performance computing infrastructure as mining profitability tightens across the sector. See our latest analysis for MARA...

In March 2026, Kanzhun Limited reported past fourth-quarter and full-year 2025 results showing higher revenue and net income, issued first-quarter 2026 revenue guidance, approved a new annual dividend policy, and expanded its share repurchase authorization to US$400 million through August 28, 2027. The decision to return at least half of adjusted net income over the next three years via dividends and buybacks highlights a stronger emphasis on capital returns alongside Kanzhun’s core online...

Event driven snapshot of Zoom Communications (ZM) Zoom Communications (ZM) recently reported annual revenue of US$4.87b and net income of US$1.90b, putting fresh attention on how the stock’s recent month gain and past 3 months decline line up with fundamentals. See our latest analysis for Zoom Communications. At a share price of US$77.71, Zoom’s 30 day share price return of 5.1% contrasts with a 90 day share price decline of 10%. The 1 year total shareholder return of 3.8% points to...

Why Andersons Stock Is On Investors’ Radar Andersons (ANDE) has drawn attention after a period of strong share price performance, with the stock showing double digit total returns over the past year and the past three months. See our latest analysis for Andersons. With the share price at $73.19, Andersons has seen strong momentum, with a 10.16% 7 day share price return and a 12.10% 30 day share price return. The 1 year total shareholder return of 72.35% highlights how sustained this trend has...

TPG (TPG) shares were in focus after reports that OpenAI is in advanced talks with the firm and other private equity groups to create a joint venture to distribute OpenAI’s enterprise products. See our latest analysis for TPG. The OpenAI talks arrive during a weak patch for TPG’s share price, which has a 1 month share price return of 9.95% and a year to date share price return of 40.53%, even though the 3 year total shareholder return is 49%. This suggests that longer term holders have still...

Q4 earnings reaction and recent stock move First American Financial (FAF) recently reported Q4 results with revenue up 21.6% year on year and earnings exceeding analyst expectations by 15.2%, yet the share price is down 7.6% since the release. See our latest analysis for First American Financial. The recent pullback leaves the share price at US$58.47, with a 30 day share price return of a 16.6% decline and a 1 year total shareholder return of a 7.9% decline, suggesting momentum has cooled...

Pony AI (PONY) is back in focus after reporting mixed fourth quarter results, with revenue of US$29.13 million, net income of US$23.43 million, and a new robotaxi partnership in Europe with Uber and Verne. See our latest analysis for Pony AI. The earnings release and new robotaxi partnerships arrive after a sharp pullback in the share price, with a 30 day share price return of a 36.26% decline and a year to date share price return of a 43.12% decline, even as the 1 year total shareholder...

Rocket Pharmaceuticals (RCKT) is back in focus after the FDA granted accelerated approval for its gene therapy KRESLADI to treat pediatric patients with severe leukocyte adhesion deficiency I who lack matched sibling donors. See our latest analysis for Rocket Pharmaceuticals. Even with the FDA approval and accompanying priority review voucher, Rocket Pharmaceuticals’ recent share price performance has been weak, with a 1-month share price return of a 24.75% decline and a 1-year total...

Recent performance and business snapshot Dolby Laboratories (DLB) has seen its share price under pressure recently, with a 1 day return of 1.19% decline and a past month move of 12.83% decline, extending to 10.93% decline over the past 3 months. Against that backdrop, the company reports annual revenue of US$1.34b and net income of US$240.52m, with revenue growth of 5.21% and net income growth of 13.34%. This reflects how its licensing and product model is currently translating into...

Recent share performance puts PPG Industries (PPG) in focus for investors Recent moves in PPG Industries (PPG) have drawn attention, with the stock showing a 1.4% decline over the past day, a 6.8% gain over the past week, and weaker returns over the past month and past 3 months. See our latest analysis for PPG Industries. At a share price of US$103.82, PPG Industries shows short term momentum with a 7 day share price return of 6.8%. However, longer term total shareholder returns over 1, 3 and...

Northern Trust (NTRS) has drawn closer attention after recent trading, with the share price at $134.99 and negative moves over the day, week, month, and past 3 months prompting fresh comparisons with its fundamentals. See our latest analysis for Northern Trust. While the recent 1 day, 1 month, and 3 month share price returns are negative, the 1 year, 3 year, and 5 year total shareholder returns of 42.45%, 68.52%, and 48.60% suggest longer term momentum has been stronger than the latest...

Denali Therapeutics announced that the U.S. Food and Drug Administration previously granted accelerated approval for AVLAYAH (tividenofusp alfa-eknm), the first biologic specifically engineered to cross the blood-brain barrier, for treating neurologic manifestations of Hunter syndrome in certain pediatric patients. This approval not only introduces a new enzyme replacement therapy for a rare pediatric disease but also validates Denali’s TransportVehicle platform as an FDA-cleared route to...

CBL & Associates Properties, Inc. recently closed a US$176 million floating-rate, non-recourse loan with Beal Bank USA, secured mainly by three lifestyle and open-air centers, as the final step in refinancing its former US$634 million secured term loan. The combined refinancings push the secured debt maturity out to 2031, trim total debt by more than US$33 million, and are expected to improve annual free cash flow by over US$30 million while leaving CBL with an estimated cash balance above...

On March 28, 2026, Arcutis Biotherapeutics presented new INTEGUMENT-INFANT Phase 2 and other ZORYVE data at the American Academy of Dermatology meeting in Denver, highlighting reduced signs and symptoms of atopic dermatitis and favorable safety across infants and young children. The company plans to use these infant trial results to support a supplemental New Drug Application for ZORYVE cream 0.05% in infants, potentially broadening its addressable patient population across age groups and...

CBIZ (CBZ) is back in focus after a federal judge rejected its bid to halt a lawsuit over an allegedly understated valuation of AmeriTex Holdings, allowing full discovery into claimed intentional breaches of duty. See our latest analysis for CBIZ. Despite the legal setback, CBIZ’s share price has struggled for some time, with a 90 day share price return of 50.62% and a 1 year total shareholder return of 65.15%, signaling fading momentum rather than a short term wobble. If this kind of legal...

Arbor Realty Trust, Inc. previously closed a US$762.6 million commercial real estate mortgage loan securitization, issuing about US$674.0 million of investment grade-rated notes and retaining roughly US$88.6 million of subordinate interests, backed primarily by first mortgage bridge loans and featuring a reinvestment period of about two and a half years. The transaction effectively refinances existing borrowings while adding capacity to acquire up to US$100.0 million of additional loans,...

In March 2026, MACOM Technology Solutions Inc. announced new 448G PAM4 modulator drivers and joined Broadcom, Cisco, NVIDIA and Semtech in forming the 400G Optical MSA to define interoperable 400G-per-wavelength interfaces for next-generation AI data center equipment. This combination of higher-speed optical components and participation in an industry standards group positions MACOM at the heart of emerging AI infrastructure connectivity, even as US-China trade tensions add uncertainty for...

GXO Logistics recently opened Hasbro’s new 600,000-square-foot flagship distribution center in Midway, Georgia, and launched its first autonomous industrial truck pilot in Épinoy, France, marking concrete advances in AI-enabled warehouse operations. These moves, underpinned by GXO IQ and collaborations with KION, NVIDIA and Accenture, show how the company is applying emerging automation technologies in real-world logistics networks at scale. We’ll now examine how the rollout of GXO...

Earlier this month, Coeur Mining replaced its 2017 credit agreement with a new five-year, US$1.00 billion senior secured revolving facility, launched a US$400 million bond-exchange offer tied to its New Gold acquisition, updated 2026 gold, silver and copper production guidance, expanded its authorized share count to 1.30 billion, and added Patrick Godin and Marilyn Schonberner to its board. Together, these financing, governance and capital-structure moves point to a company reshaping its...

MoonLake Immunotherapeutics recently reported long-term Week 40 data from its Phase 3 VELA-1 and VELA-2 trials of sonelokimab in moderate-to-severe hidradenitis suppurativa, showing sustained clinical responses, meaningful quality-of-life improvements and a stable safety profile. An especially distinctive takeaway is that sonelokimab reached high rates of deep lesion clearance and inflammatory remission on multiple rigorous HS scoring measures, suggesting a potentially higher treatment bar...

American Assets Trust (AAT) has been drawing attention after recent share performance, with the stock near US$18 and returns over the month and past 3 months tracking in negative territory. See our latest analysis for American Assets Trust. At a share price of US$18.18, American Assets Trust has seen a 6.9% 1 month share price decline and a 3.2% year to date share price decline. The 3 year total shareholder return of 18.0% contrasts with a 28.1% total shareholder return decline over 5 years,...

Why Celldex Therapeutics Is On Investors’ Radar Celldex Therapeutics (CLDX) has recently caught investor attention without a single headline event driving the story. This naturally shifts the focus toward its recent share performance and underlying business profile. See our latest analysis for Celldex Therapeutics. At a share price of $30.30, Celldex Therapeutics has seen a 16.4% 90 day share price return and a 52.0% 1 year total shareholder return. This suggests recent momentum has...

In the past week, O'Reilly Automotive drew attention as it approached its first-quarter earnings release, with analysts forecasting a double-digit adjusted EPS increase and management guiding for comparable store sales growth of 3% to 5% alongside an EPS outlook for 2026 between $3.10 and $3.20. Despite a recent period of weaker share performance and softer quarterly results, O'Reilly continues to post average same-store sales growth of 3.8% per year over the last two years while sustaining...